ULTRACET
LOE ApproachingNDAORALTABLET
Approved
Aug 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
7
Data completeness
3/8 — Basic
ULTRACET by Johnson & Johnson is clinical pharmacology the following information is based on studies of tramadol alone or acetaminophen alone, except where otherwise noted: pharmacodynamics ultracet contains tramadol and acetaminophen. First approved in 2001.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ULTRACET is an oral tablet combination product approved by Johnson & Johnson in 2001 for pain management. The specific generic composition and mechanism of action are not publicly detailed in available records. It represents a small-molecule therapeutic in the pain management category.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30), suggesting a contracting team and shift toward generic transition planning rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY The following information is based on studies of tramadol alone or acetaminophen alone, except where otherwise noted: Pharmacodynamics ULTRACET contains tramadol and acetaminophen. Tramadol is a centrally acting synthetic opioid analgesic. Although its mode of action is not…
Worked on ULTRACET at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.